Related Experiment Videos
[Study on the rifampicin polylactic acid microspheres for lung targeting]
Abstract:
In this paper, the effects of different variables on the preparation of polylactic acid microspheres (PLA-MS) were studied. The optimized preparation conditions of rifampicin polylactic acid microspheres (RFP-PLA-MS) were aquired through orthogonal test. The paddle method was used to study the drug release properties of RFP-PLA-MS. Stability of RFP-PLA-MS at different temperatures was also studied. Pharmacokinetic and tissue distribution of RFP-PLA-MS after intravenous administration were carried out in rabbits. The experiments revealed that the RFP-PLA-MS was regular in its morphology with a mean diameter of 9.00 +/- 4.08 microns. The drug loading was 16.0% and encapsulation efficiency was 31.9%. The release properties could be expressed by the following equation: Q = 20.77 + 10.12 T 1/2 (gamma = 0.9892). The RFP-PLA-MS was stable after stored at 4 degrees C and room temperature under desiccated condition for three months. RFP-PLA-MS showed a combination of lung targeting and sustained drug release in experiments on rabbits.
Insights
Optimized rifampicin polylactic acid microspheres (RFP-PLA-MS) exhibit sustained drug release and lung targeting. These microspheres demonstrate stability and suitable characteristics for potential therapeutic applications.
Area of Science:
- Biomaterials Science
- Pharmaceutical Technology
- Drug Delivery Systems
Background:
- Polylactic acid microspheres (PLA-MS) are crucial for controlled drug release.
- Rifampicin (RFP) is a key antibiotic requiring effective delivery systems.
- Optimizing RFP-PLA-MS preparation is essential for enhanced therapeutic efficacy.
Purpose of the Study:
- To optimize the preparation of rifampicin polylactic acid microspheres (RFP-PLA-MS).
- To characterize the physicochemical properties, drug release, and stability of RFP-PLA-MS.
- To evaluate the pharmacokinetic and tissue distribution of RFP-PLA-MS in rabbits.
Main Methods:
- Orthogonal experimental design for optimizing RFP-PLA-MS preparation.
- Paddle method for assessing in vitro drug release kinetics.
- Stability studies at various temperatures and conditions.
- In vivo pharmacokinetic and tissue distribution analysis in rabbits.
Main Results:
- Optimized RFP-PLA-MS displayed regular morphology (9.00 ± 4.08 µm), 16.0% drug loading, and 31.9% encapsulation efficiency.
- Drug release followed the equation Q = 20.77 + 10.12 T 1/2 (γ = 0.9892).
- RFP-PLA-MS remained stable for three months under specified storage conditions.
Conclusions:
- Optimized RFP-PLA-MS formulation achieved desired characteristics for sustained drug delivery.
- The microspheres demonstrated significant lung targeting and sustained release in vivo.
- These findings support the potential of RFP-PLA-MS for improved rifampicin therapy.